ResMed executives adjust stock holdings, dividend exchange rate updated

ResMed Inc. reported significant changes in stock ownership by two executives. chairman and chief executive Michael J. Farrell engaged in multiple transactions on November 7, 2025. He acquired 983 and 7,028 shares of common stock at $101.64 per share through option exercises, bringing his direct beneficial ownership to 475,877 shares, and disposed of 8,011 shares at $249.7532. Additionally, Farrell holds 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

Michael J. Rider, global general counsel and secretary, disposed of 135.075, 173.725, 715.489, and 500.735 shares of common stock, each at $250.10, between November 11 and November 20, 2025, for tax withholding purposes related to vesting Restricted Stock Units. After these transactions, Rider's direct beneficial ownership totaled 9,841 shares.

Jan De Witte, a director, also reported a disposal of 487 shares on November 11, 2025, related to restricted stock vesting, with an aggregate market value of $121,871.75. The transactions by Farrell and Rider, particularly the option exercises, were conducted under a Rule 10b5-1 plan adopted in October 2024.

Concurrently, ResMed Inc. announced an update to the foreign exchange rate for its upcoming ordinary dividend. For holders of CDIs trading on the ASX, the exchange rate for the dividend is 0.6529 U.S. dollars for 1.00 Australian dollar, resulting in an Australian currency dividend of 0.0919 Australian dollar per CDI. The total dividend payment is $0.06000000 per security, with a 30.000000% withholding tax rate for Australian residents, which can be reduced to 15% with appropriate forms. The dividend's record date is November 13, 2025, with a payment date of December 18, 2025.